HK1084037A1 - Medicament for treating severe heart failure - Google Patents

Medicament for treating severe heart failure

Info

Publication number
HK1084037A1
HK1084037A1 HK06104485.8A HK06104485A HK1084037A1 HK 1084037 A1 HK1084037 A1 HK 1084037A1 HK 06104485 A HK06104485 A HK 06104485A HK 1084037 A1 HK1084037 A1 HK 1084037A1
Authority
HK
Hong Kong
Prior art keywords
medicament
heart failure
severe heart
treating severe
treating
Prior art date
Application number
HK06104485.8A
Other languages
English (en)
Inventor
Atsushi Ozaki
Yosuke Maki
Osamu Sato
Yoshitaka Yamamura
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32908667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1084037(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of HK1084037A1 publication Critical patent/HK1084037A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK06104485.8A 2003-02-24 2006-04-12 Medicament for treating severe heart failure HK1084037A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44887803P 2003-02-24 2003-02-24
PCT/JP2004/002085 WO2004073716A1 (en) 2003-02-24 2004-02-23 Method for treating severe heart failure and medicament therefor

Publications (1)

Publication Number Publication Date
HK1084037A1 true HK1084037A1 (en) 2006-07-21

Family

ID=32908667

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06104485.8A HK1084037A1 (en) 2003-02-24 2006-04-12 Medicament for treating severe heart failure

Country Status (24)

Country Link
US (2) US7423032B2 (xx)
EP (2) EP1596868B1 (xx)
JP (2) JP4771937B2 (xx)
KR (1) KR100706727B1 (xx)
CN (1) CN100577171C (xx)
AR (1) AR043259A1 (xx)
AT (1) ATE411803T1 (xx)
AU (2) AU2004212842B9 (xx)
BR (1) BRPI0405657A (xx)
CA (1) CA2493475A1 (xx)
CY (1) CY1108583T1 (xx)
DE (1) DE602004017283D1 (xx)
DK (1) DK1596868T3 (xx)
ES (1) ES2315640T3 (xx)
HK (1) HK1084037A1 (xx)
MX (1) MXPA05001623A (xx)
MY (1) MY143740A (xx)
NO (1) NO335369B1 (xx)
PL (2) PL218069B1 (xx)
PT (1) PT1596868E (xx)
RU (2) RU2346689C2 (xx)
SI (1) SI1596868T1 (xx)
TW (1) TWI322689B (xx)
WO (1) WO2004073716A1 (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468390B2 (en) * 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor
DE102005003632A1 (de) 2005-01-20 2006-08-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Katheter für die transvaskuläre Implantation von Herzklappenprothesen
US20070213813A1 (en) 2005-12-22 2007-09-13 Symetis Sa Stent-valves for valve replacement and associated methods and systems for surgery
CA2633929A1 (en) 2005-12-27 2007-07-05 Otsuka Pharmaceutical Co., Ltd. Water-soluble benzoazepine compound and its pharmaceutical composition
JP5076327B2 (ja) * 2006-02-01 2012-11-21 味の素株式会社 分岐鎖アミノ酸の心不全適応
US7896915B2 (en) 2007-04-13 2011-03-01 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
DK2146721T3 (da) * 2007-05-15 2013-07-22 Otsuka Pharma Co Ltd Fremgangsmåder til anvendelse af vasopressinantagonister med anthracyclin-kemoterapi-midler til reduktion af kardiotoksicitet og/eller forbedring af overlevelse
TWI405574B (zh) * 2007-06-21 2013-08-21 Otsuka Pharma Co Ltd 藥學固體製劑及其製造方法
US9044318B2 (en) 2008-02-26 2015-06-02 Jenavalve Technology Gmbh Stent for the positioning and anchoring of a valvular prosthesis
WO2011104269A1 (en) 2008-02-26 2011-09-01 Jenavalve Technology Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
CA2799459A1 (en) 2010-05-25 2011-12-01 Jenavalve Technology Inc. Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent
JP5477413B2 (ja) * 2012-04-24 2014-04-23 味の素株式会社 分岐鎖アミノ酸の心不全適応
CN105491978A (zh) 2013-08-30 2016-04-13 耶拿阀门科技股份有限公司 用于假体瓣膜的径向可折叠框架及其制造方法
US10709555B2 (en) 2015-05-01 2020-07-14 Jenavalve Technology, Inc. Device and method with reduced pacemaker rate in heart valve replacement
EP4183371A1 (en) 2016-05-13 2023-05-24 JenaValve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system
EP3573579B1 (en) 2017-01-27 2023-12-20 JenaValve Technology, Inc. Heart valve mimicry
CN110174474B (zh) * 2019-05-24 2022-02-18 石家庄四药有限公司 复方电解质注射液(ⅱ)中l-苹果酸异构体的检测方法
CN112121051B (zh) * 2020-09-30 2021-06-18 郑州大学 莫扎伐坦在制备抗消化道肿瘤药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258510A (en) 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
US5753677A (en) 1989-10-20 1998-05-19 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
ES2089033T3 (es) 1989-10-20 1996-10-01 Otsuka Pharma Co Ltd Compuestos benzoheterociclicos.
TW249201B (xx) 1992-07-02 1995-06-11 Otsuka Pharma Co Ltd
JPH0680641A (ja) 1992-09-01 1994-03-22 Otsuka Pharmaceut Co Ltd 光学活性な５−ヒドロキシベンゾアゼピン誘導体の製造法
TW354762B (en) 1993-02-23 1999-03-21 Otsuka Pharma Co Ltd Agent for prophylaxis or treatment of cataract
JP2694319B2 (ja) 1993-12-24 1997-12-24 大塚製薬株式会社 抗潰瘍剤
JP3002766B2 (ja) 1994-12-09 2000-01-24 大塚製薬株式会社 脳浮腫治療剤
JPH10120592A (ja) 1996-10-22 1998-05-12 Otsuka Pharmaceut Co Ltd メニエール病乃至メニエール症候群治療剤
JP4210355B2 (ja) * 1997-07-03 2009-01-14 大塚製薬株式会社 固形製剤組成物
US20030103983A1 (en) * 2002-05-09 2003-06-05 Pressler Milton Lethan Ace inhibitor-vasopressin antagonist combinations
WO2001054677A2 (en) 2000-01-26 2001-08-02 Warner-Lambert Company Ace inhibitor-vasopressin antagonist combinations
US20030008860A1 (en) 2002-05-09 2003-01-09 Bakker-Arkema Rebecca Guggemos Treatment of congestive heart failure
ATE367815T1 (de) * 2000-10-04 2007-08-15 Astellas Pharma Inc Verwendung von einem vasopressin-antagonisten wie conivaptan zur herstellung eines medikaments für die behandlung der pulmonalen hypertension
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor

Also Published As

Publication number Publication date
DE602004017283D1 (de) 2008-12-04
AR043259A1 (es) 2005-07-20
RU2346689C2 (ru) 2009-02-20
AU2004212842B9 (en) 2009-03-05
JP2011148806A (ja) 2011-08-04
CY1108583T1 (el) 2014-04-09
RU2008133654A (ru) 2010-02-20
KR100706727B1 (ko) 2007-04-12
NO335369B1 (no) 2014-12-01
MY143740A (en) 2011-07-15
SI1596868T1 (sl) 2008-12-31
EP1596868B1 (en) 2008-10-22
KR20050105972A (ko) 2005-11-08
AU2004212842A1 (en) 2004-09-02
PL218069B1 (pl) 2014-10-31
RU2005102110A (ru) 2005-09-20
WO2004073716A1 (en) 2004-09-02
US7749993B2 (en) 2010-07-06
US20080214523A1 (en) 2008-09-04
AU2004212842B2 (en) 2009-01-08
EP2000142A1 (en) 2008-12-10
US20050187210A1 (en) 2005-08-25
CN1700919A (zh) 2005-11-23
NO20050569L (no) 2005-11-22
CN100577171C (zh) 2010-01-06
EP1596868A4 (en) 2006-03-29
AU2009201109A1 (en) 2009-04-09
JP4771937B2 (ja) 2011-09-14
US7423032B2 (en) 2008-09-09
PL404315A1 (pl) 2013-08-05
MXPA05001623A (es) 2005-04-25
ES2315640T3 (es) 2009-04-01
ATE411803T1 (de) 2008-11-15
TW200418489A (en) 2004-10-01
PT1596868E (pt) 2009-01-14
CA2493475A1 (en) 2004-09-02
NO20050569D0 (no) 2005-02-02
JP2006518731A (ja) 2006-08-17
TWI322689B (en) 2010-04-01
DK1596868T3 (da) 2008-12-08
EP1596868A1 (en) 2005-11-23
PL373432A1 (en) 2005-08-22
BRPI0405657A (pt) 2005-07-19

Similar Documents

Publication Publication Date Title
HK1084037A1 (en) Medicament for treating severe heart failure
HK1079993A1 (en) Drugs for treating vascular diseases
GB0218879D0 (en) Medical treatment
GB0300428D0 (en) Medical treatment
GB0327493D0 (en) Treatment medicament
GB0307472D0 (en) Medical treatment
AU2003900407A0 (en) Treatment for heart failure
GB0306165D0 (en) Medical treatment
AUPS020602A0 (en) Treatment for heart failure
AU2004900503A0 (en) Treatment for heart failure
GB0220912D0 (en) Medical treatment
GB0220913D0 (en) Medical treatment
GB0223405D0 (en) Medical treatment
GB0223528D0 (en) Medical treatment
GB0224353D0 (en) Medical treatment
GB0227865D0 (en) Medical Treatment
GB0220849D0 (en) Medical treatment
GB0218068D0 (en) Medical treatment
GB0223409D0 (en) Medical treatment
GB0301518D0 (en) Medical treatment
GB0301522D0 (en) Medical treatment
GB0301526D0 (en) Medical treatment
GB0301527D0 (en) Medical treatment
GB0301529D0 (en) Medical treatment
GB0301521D0 (en) Medical treatment

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20240222